drug activation
Recently Published Documents


TOTAL DOCUMENTS

79
(FIVE YEARS 22)

H-INDEX

19
(FIVE YEARS 4)

Exploration ◽  
2021 ◽  
Vol 1 (3) ◽  
pp. 20210023
Author(s):  
Li Tu ◽  
Zhihuan Liao ◽  
Zheng Luo ◽  
Yun‐Long Wu ◽  
Andreas Herrmann ◽  
...  

Exploration ◽  
2021 ◽  
Vol 1 (3) ◽  
pp. 20210329
Author(s):  
Li Tu ◽  
Zhihuan Liao ◽  
Zheng Luo ◽  
Yun‐Long Wu ◽  
Andreas Herrmann ◽  
...  

Author(s):  
Jie Yao ◽  
Tongyu Li ◽  
Xiaowei Shi ◽  
Yuchen Wang ◽  
Shijiang Fang ◽  
...  
Keyword(s):  

Drug Research ◽  
2021 ◽  
Author(s):  
Seyedeh Mahsa Poormoosavi ◽  
Mohammad Amin Behmanesh ◽  
Hamed Abeyat ◽  
Ehsan Sangtarash

Abstract Background Tacrolimus is an immunosuppressive drug. Activation of the renin-angiotensin system (RAS) and associated inflammations may exacerbate the toxic effects of tacrolimus. Given the significant role of the kidney in RAS this study aimed to evaluate the effect of captopril as an angiotensin-converting enzyme (ACE) blocker and losartan as an angiotensin II receptor blocker on tacrolimus-induced nephrotoxicity. Materials and Methods In total, 36 adult male rats weighing 200–250 gr were completely randomized and divided into six groups (control, tacrolimus, tacrolimus and losartan, tacrolimus and captopril, losartan, and captopril) for 30 days. Afterwards, blood urea nitrogen (BUN), creatinine (Cr) and ACE2 enzyme were measured. Also, both kidneys were collected for histological examinations. Results The level of BUN and Cr significantly increased in tacrolimus group. The level of BUN and Cr were lower in the groups treated with a combination of tacrolimus and losartan or captopril. While ACE2 level increased in the groups receiving a combination of tacrolimus and losartan or captopril, the level of increase was insignificant, compared to the group treated with tacrolimus alone. The glomerulus diameter and the thickness of the renal proximal tubular epithelium significantly decreased in the group treated with tacrolimus alone. the mentioned variables increased in the group treated with a combination of tacrolimus and losartan or captopril, compared to the tacrolimus group. Conclusion According to this study, tacrolimus increased the BUN and Cr levels while decreasing the ACE2 levels. However, tacrolimus in combination with losartan or captopril seemed to decrease the nephrotoxicity of the drug.


Biomaterials ◽  
2021 ◽  
pp. 120649
Author(s):  
Xuan Xiao ◽  
Kewei Wang ◽  
Qingyu Zong ◽  
Yalan Tu ◽  
Yansong Dong ◽  
...  

2021 ◽  
Vol 14 ◽  
pp. 117863612199712
Author(s):  
Cheng-Hsuan Li ◽  
Rui Huang ◽  
Jessa Marie Makabenta ◽  
Suzannah Schmidt-Malan ◽  
Robin Patel ◽  
...  

Prodrug strategies use chemical modifications to improve the pharmacokinetic properties and therefore therapeutic effects of parent drugs. Traditional prodrug approaches use endogenous enzymes for activation. Bioorthogonal catalysis uses processes that endogenous enzymes cannot access, providing a complementary strategy for prodrug uncaging. Site-selective activation of prodrugs to drugs (uncaging) using synthetic catalysts is a promising strategy for localized drug activation. We discuss here recent studies that incorporate metal catalysts into polymers and nanoparticle scaffolds to provide biocompatible “enzyme-like” catalysts that can penetrate bacterial biofilms and activate prodrug antibiotics in situ, affording a new strategy to treat bacterial biofilm infections with the potential for reduced off-target effects.


Theranostics ◽  
2021 ◽  
Vol 11 (9) ◽  
pp. 4137-4154
Author(s):  
Jianqin Wan ◽  
Lingling Huang ◽  
Jiangting Cheng ◽  
Huangfu Qi ◽  
Jiahui Jin ◽  
...  

2020 ◽  
pp. jbc.RA120.016115
Author(s):  
Wenchuan Ma ◽  
Victoria A. Balta ◽  
Rachel West ◽  
Katy N. Newlin ◽  
Ognjen Š. Miljanić ◽  
...  

Malaria is a pervasive disease that affects millions of lives each year in equatorial regions of the world. During the erythrocytic phase of the parasite life cycle, Plasmodium falciparum invade red blood cells, where they catabolize hemoglobin and sequester the released toxic heme as innocuous hemozoin crystals. Artemisinin-class drugs are activated in vivo by newly-released heme, which creates a carbon-centered radical that markedly reduces parasite density. Radical damage to parasite lipids and proteins is perceived to be artemisinins’ dominant mechanism of action. By contrast, quinoline-class antimalarials inhibit the formation of hemozoin and in this way suppress heme detoxification. Here, we combine malaria parasite assays and scanning probe microscopy of growing beta-hematin crystals to elucidate an unexpected mechanism employed by two widely administered antimalarials, artemisinin and artesunate, to subdue the erythrocytic phase of the parasite life cycle. We demonstrate that heme-drug adducts, produced after the radical activation of artemisinins and largely believed to be benign bystanders, potently kills P. falciparum at low concentrations. We show that these adducts inhibit b-hematin crystallization and heme detoxification, a pathway which complements the deleterious effect of radicals generated via parent drug activation. Our findings reveal an irreversible mechanism of heme-artemisinin adduct inhibition of heme crystallization, unique among antimalarials and common crystal growth inhibitors, that opens new avenues for evaluating drug dosing regimens and understanding growing resistance of P. falciparum to artemisinin.


2020 ◽  
Author(s):  
Almut Heinken ◽  
Geeta Acharya ◽  
Dmitry A. Ravcheev ◽  
Johannes Hertel ◽  
Malgorzata Nyga ◽  
...  

AbstractThe human microbiome influences the efficacy and safety of a wide variety of commonly prescribed drugs, yet comprehensive systems-level approaches to interrogate drug-microbiome interactions are lacking. Here, we present a computational resource of human microbial genome-scale reconstructions, deemed AGORA2, which accounts for 7,206 strains, includes microbial drug degradation and biotransformation, and was extensively curated based on comparative genomics and literature searches. AGORA2 serves as a knowledge base for the human microbiome and as a metabolic modelling resource. We demonstrate the latter by mechanistically modelling microbial drug metabolism capabilities in single strains and pairwise models. Moreover, we predict the individual-specific drug conversion potential in a cohort of 616 colorectal cancer patients and controls. This analysis reveals that some drug activation capabilities are present in only a subset of individuals, moreover, drug conversion potential correlate with clinical parameters. Thus, AGORA2 paves the way towards personalised, predictive analysis of host-drug-microbiome interactions.


2020 ◽  
Vol 63 (22) ◽  
pp. 13899-13912
Author(s):  
Tao Sun ◽  
Tian Lv ◽  
Jianbing Wu ◽  
Mingchao Zhu ◽  
Yue Fei ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document